biostudies-literatureCorry SMCancer Research UKMedical Research CouncilPublic Health AgencyWellcome TrustBiotechnology and Biological Sciences Research Council2502-2517https://www.ebi.ac.uk/biostudies/studies/S-EPMC9664095biostudies-literatureUnknown71(12)<h4>Objective</h4>Stroma-rich tumours represent a poor prognostic subtype in stage II/III colon cancer (CC), with high relapse rates and limited response to standard adjuvant chemotherapy.<h4>Design</h4>To address the lack of efficacious therapeutic options for patients with stroma-rich CC, we stratified our human tumour cohorts according to stromal content, enabling identification of the biology underpinning relapse and potential therapeutic vulnerabilities specifically within stroma-rich tumours that could be exploited clinically. Following human tumour-based discovery and independent clinical validation, we use a series of <i>in vitro</i> and stroma-rich <i>in vivo</i> models to test and validate the therapeutic potential of elevating the biology associated with reduced relapse in humanGutActivation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.PMC9664095MC_PC_17117A3128715333A282232438729834EAT/4905/13A17196MR/M016587/1A26825MR/S021205/126045206314/Z/17/ZA21139A29834S_4137BB/T002824/1STL/5175/15110371/Z/15/ZG0400302Maguire SMalla SBWhite MAmirkhah RLawler MColeman HGMcCooey AJKerr EMMaughan TTejpar SLeonard NALeedham SJTsantoulis PSmall DMSakhnevych SS:CORT and ACRCelerate consortiaCortes-Lavaud XLoughrey MBJackstadt RFLannagan TRGillespie MAMcCorry AMCorry SMFisher NCCampbell ADMcDade SSByrne RMRichman SDRedmond KLSansom OJRyan AELongley DBDunne PDRogan EfalseActivation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.<h4>Objective</h4>Stroma-rich tumours represent a poor prognostic subtype in stage II/III colon cancer (CC), with high relapse rates and limited response to standard adjuvant chemotherapy.<h4>Design</h4>To address the lack of efficacious therapeutic options for patients with stroma-rich CC, we stratified our human tumour cohorts according to stromal content, enabling identification of the biology underpinning relapse and potential therapeutic vulnerabilities specifically within stroma-rich tumours that could be exploited clinically. Following human tumour-based discovery and independent clinical validation, we use a series of <i>in vitro</i> and stroma-rich <i>in vivo</i> models to test and validate the therapeutic potential of elevating the biology associated with reduced relapse in human2022-01-01T00:00:00Z2022 Dec2026-06-15T05:54:05.985Z2024-11-12T17:37:03.615ZS-EPMC96640953547753910.1136/gutjnl-2021-326183